Airflow limitation by the Global Lungs Initiative equations in a cohort of very old adults

European Respiratory Journal

Volumn 46, Issue 1, 2015, Pages 123-132

  Turkeshi, Eralda ^a   Vaes, Bert ^a,b   Andreeva, Elena ^a   Matheï, Catharina ^a,b   Adriaensen, Wim ^a,b   Van Pottelbergh, Gijs ^a,b   Degryse, Jean Marie ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AIRFLOW LIMITATION; ALL CAUSE MORTALITY; ARTICLE; BELGIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENERAL PRACTITIONER; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY AIRFLOW; RISK ASSESSMENT; VERY ELDERLY; BELGIUM; KAPLAN MEIER METHOD; LUNG; LUNG DISEASE; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SPIROMETRY; VITAL CAPACITY;

AGED, 80 AND OVER; BELGIUM; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG; LUNG DISEASES; MALE; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; VITAL CAPACITY;

EID: 84937421915     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00217214     Document Type: Article

References (39)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2015). GOLD, 2015. Available from www.goldcopd.org
3. Quanjer PH. Correctly defining criteria for diagnosing chronic obstructive pulmonary disease matters. Am J Respir Crit Care Med 2014; 189: 230.
4. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
5. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968.
6. Stanojevic S, Wade A, Stocks J. Reference values for lung function: past, present and future. Eur Respir J 2010; 36: 12-19.
7. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324-1343.
8. Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008; 177: 253-260.
9. Vaz Fragoso CA, Concato J, McAvay G, et al. The ratio of FEV1 to FVC as a basis for establishing chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 446-451.
10. Vaz Fragoso CA, Gill TM, McAvay G, et al. Respiratory impairment in older persons: when less means more. Am J Med 2013; 126: 49-57.
11. Akkermans RP, Biermans M, Robberts B, et al. COPD prognosis in relation to diagnostic criteria for airflow obstruction in smokers. Eur Respir J 2014; 43: 54-63.
12. van Dijk WD, Gupta N, Tan WC, et al. Clinical relevance of diagnosing COPD by fixed ratio or lower limit of normal: a systematic review. COPD 2014; 11: 113-120.
13. Dept of Economic and Social Affairs, Population Division. World Population Ageing, 2009. New York, United Nations, 2009.
14. Vaes B, Pasquet A, Wallemacq P, et al. The BELFRAIL (BFC80+) study: a population-based prospective cohort study of the very elderly in Belgium. BMC Geriatr 2010; 10: 39.
15. Degryse J, Buffels J, Van Dijck Y, et al. Accuracy of office spirometry performed by trained primary-care physicians using the MIR Spirobank hand-held spirometer. Respiration 2012; 83: 543-552.
16. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
17. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
18. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21.
19. Leening MJ, Vedder MM, Witteman JC, et al. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. Ann Intern Med 2014; 160: 122-131.
20. Vaz Fragoso CA, Gill TM, McAvay G, et al. Respiratory impairment and mortality in older persons: a novel spirometric approach. J Investig Med 2011; 59: 1089-1095.
21. Mohamed Hoesein FA, Zanen P, Lammers JW. Lower limit of normal or FEV1/FVC <0.70 in diagnosing COPD: an evidence-based review. Respir Med 2011; 105: 907-915.
22. Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J 2013; 42: 1046-1054.
23. Güder G, Brenner S, Angermann CE, et al. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res 2012; 13: 13.
24. Arne M, Lisspers K, Ställberg B, et al. How often is diagnosis of COPD confirmed with spirometry? Respir Med 2010; 104: 550-556.
25. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010; 36: 531-539.
26. Rennard SI, Vestbo J, Agusti A. What is chronic obstructive pulmonary disease anyway? Continua, categories, cut points, and moving beyond spirometry. Am J Respir Crit Care Med 2013; 187: 1036-1037.
27. Coultas DB, Davis K. Hidden realities of COPD among the very old. In: Bellia V, Antonelli Incalzi R, eds. Respiratory Diseases in the Elderly. ERS Monogr 2009; 43: 77-89.
28. Güder G, Rutten FH. Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence. Curr Heart Fail Rep 2014; 11: 337-346.
29. Rutten FH, Moons KG, Cramer MJ, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005; 331: 1379.
30. Vaes B, Delgado V, Bax J, et al. Diagnostic accuracy of plasma NT-proBNP levels for excluding cardiac abnormalities in the very elderly. BMC Geriatr 2010; 10: 85.
31. deFilippi CR, Seliger SL, Maynard S, et al. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 2007; 53: 1511-1519.
32. Mannino DM, Buist AS, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax 2007; 62: 237-241.
33. Mannino DM, Diaz-Guzman E. Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. Chest 2012; 141: 73-80.
34. Miller MR. Lung function data interpretation. Chest 2012; 141: 832-833.
35. Quanjer PH, Pretto JJ, Brazzale DJ, et al. Grading the severity of airways obstruction: new wine in new bottles. Eur Respir J 2014; 43: 505-512.
36. Burgel PR, Roche N, Paillasseur JL, et al. Clinical COPD phenotypes identified by cluster analysis: validation with mortality. Eur Respir J 2012; 40: 495-496.
37. Vollmer WM, Gislason T, Burney P, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J 2009; 34: 588-597.
38. Mannino DM, Diaz-Guzman E, Buist S. Pre-and post-bronchodilator lung function as predictors of mortality in the Lung Health Study. Respir Res 2011; 12: 136.
39. Miller MR, Thinggaard M, Christensen K, et al. Best lung function equations for the very elderly selected by survival analysis. Eur Respir J 2014; 43: 1338-1346.